Toutes les études
RecrutementExploratoire thérapeutique (Phase II)Interventionnel

AN OPEN-LABEL, MULTICENTER, GLOBAL PHASE II BASKET STUDY OF ENTRECTINIB FOR THE TREATMENT OF PATIENTS WITH LOCALLY ADVANCED OR METASTATIC SOLID TUMORS THAT HARBOR NTRK1/2/3, ROS1, OR ALK GENE REARRANGEMENTS

This clinical study is testing a targeted medicine called Rozlytrek (also known as entrectinib) in adults with advanced solid tumours. It is designed for cancers that have spread or cannot be removed with surgery, and that carry specific genetic faults known as NTRK, ROS1, or ALK gene rearrangements. Unlike traditional cancer trials that look only at where cancer started, this 'basket' trial focuses on the tumour's genetic makeup. Participants take Rozlytrek capsules by mouth once a day at home. Doctors want to measure how well the drug shrinks tumours, how long the treatment works, and whether it can reach and treat tumours that have spread to the brain. The study will also track side effects, bone strength, heart rhythm, and everyday quality of life. Taking part is completely voluntary and will not affect your standard NHS rights.

En un coup d'œil

Statut
Recrutement
Phase
Exploratoire thérapeutique (Phase II)
Sponsor
F. Hoffmann-La Roche AG
Objectif d'inscription
131
Démarrer
27 juin 2024

De quoi parle cette étude ?

Cancer can start when certain changes happen inside the genes of our cells. In some tumours, pieces of genes called NTRK, ROS1, or ALK accidentally join together with other genes. These changes act like a broken switch that stays turned on, sending non-stop signals that make cancer cells grow and spread.

Rozlytrek is a targeted treatment designed to turn that switch off. It works by blocking the proteins made by these faulty genes, which may slow down or stop the cancer from growing. Because this trial groups patients by their tumour's gene fault rather than where the cancer started in the body, it is called a 'basket trial'. This means people with many different types of cancer—such as lung, bowel, breast, or thyroid cancer—can take part if they have the matching gene change.

Researchers are carrying out this Phase II study to find out what proportion of patients see their tumours shrink or disappear entirely. They will also look closely at how well the medicine protects or treats the brain, because Rozlytrek was specially designed to cross into the brain. In addition, the study team will track safety, heart health, bone density, and general well-being to make sure the treatment is as safe and manageable as possible.

Points clés

  • Tests Rozlytrek (entrectinib), a daily targeted capsule taken at home.
  • Open to adults with advanced solid tumours carrying NTRK, ROS1, or ALK gene changes.
  • Aims to shrink tumours, including those that have spread to the brain.
  • Involves regular clinic visits for scans, blood tests, heart checks, and bone scans.
  • Participation is completely voluntary and you can leave the study at any time.

Qui peut être éligible ?

This trial is open to adults aged 18 and over who have a solid tumour that is locally advanced (cannot be removed by surgery) or metastatic (has spread to other parts of the body).

To be considered, your tumour must have been tested in a laboratory and found to have a specific genetic change in the NTRK1, NTRK2, NTRK3, ROS1, or ALK genes. People with tumours that have spread to the brain may still be able to join, provided the brain tumours meet certain safety rules.

You must also be well enough to carry out daily self-care and have reasonably normal liver, kidney, and bone marrow function. Your doctor or study team will review your complete medical history and current medications to confirm if joining is safe for you.

Cet étude pourrait-elle vous convenir ?

Répondez à ces questions rapides pour voir si vous êtes éligible. Ceci est un guide uniquement — l'équipe de recherche prend la décision finale.

  1. I am aged 18 or older.
  2. I have been diagnosed with an advanced or metastatic solid tumour.
  3. My cancer has been confirmed to have an NTRK1/2/3, ROS1, or ALK gene rearrangement.
  4. My cancer cannot be completely removed by surgery.
  5. I am able to swallow capsules whole every day.
  6. I am well enough to attend regular hospital appointments for tests and scans.
Répondez à chaque question pour voir votre résultat.

En quoi consiste la participation ?

If you take part, you will be given Rozlytrek in 200 mg capsules to swallow by mouth once a day. You will need to visit the hospital clinic regularly, especially during the first few months, so the medical team can check how you are doing.

At these visits, you will have routine health checks, including blood and urine tests, physical examinations, and heart rhythm tests (called ECGs). You will have regular imaging scans (such as CT or MRI scans, including brain scans) to see how your tumour is responding. You will also have bone density scans (called DXA scans) and complete short surveys about your energy and quality of life.

You will continue taking the study medicine for as long as your cancer stays stable or shrinks and you do not experience unacceptable side effects. Even after you stop taking the capsules, the study team will keep in touch periodically to check on your general health.

Risques et avantages potentiels

The possible benefit of taking part is that Rozlytrek may shrink your cancer, ease symptoms, or keep the tumour from growing for a period of time, even if it has spread to the brain. However, there is no guarantee that the medicine will work for you. Like all cancer medicines, Rozlytrek can cause side effects. Common ones can include tiredness, dizziness, taste changes, constipation, weight gain, or swelling. There are also risks of changes to heart rhythms or bone health, which will be monitored very closely. Taking part is entirely your choice, and you can withdraw from the study at any time without giving a reason and without your normal medical care being affected.

Emplacements (6)

Certains emplacements de site sont approximatifs. Nous améliorons cela — veuillez vérifier avec l'équipe d'essai avant de vous déplacer.
  • —
    Non vérifié
    Allemagne
  • —
    Non vérifié
    Espagne
  • —
    Non vérifié
    Pays-Bas
  • —
    Non vérifié
    Italie
  • —
    Non vérifié
    Pologne
  • —
    Non vérifié
    France

Questions fréquentes

What is a 'basket trial'?

A basket trial tests a medicine in people who have the same genetic fault in their cancer, regardless of whether the tumour started in the lung, bowel, skin, or elsewhere.

How do I know if I have an NTRK, ROS1, or ALK gene change?

This requires a specialised genomic test done on a sample of your tumour or blood. Your cancer specialist can tell you if your tumour has already been tested or if testing can be arranged.

Will I have to stay overnight in the hospital?

No, Rozlytrek is a capsule you take at home. Most study visits are outpatient clinic appointments for scans, blood tests, and doctor check-ups.

Can I take part if the cancer has spread to my brain?

Yes, patients with brain metastases may be eligible. One of the main goals of the trial is to see how well Rozlytrek works on tumours inside the brain.

What happens if the treatment stops working for me?

If scans show your cancer is growing or if side effects become too difficult, your study doctor will stop the trial medicine and discuss the best alternative care options with you.

Comment en savoir plus

Parlez toujours à votre médecin généraliste ou spécialiste avant de décider de participer à une étude.

Intéressé à participer ?

Inscrivez votre intérêt

Partagez vos coordonnées et l'équipe de recherche pour "AN OPEN-LABEL, MULTICENTER, GLOBAL PHASE II BASKET STUDY OF … vous contactera si vous êtes éligible. Consultez toujours votre médecin avant d'accepter de participer.

Discussion

Discussion communautaire

Propulsé par notre forum à community.patient.info. Veuillez être respectueux — ceci n'est pas un avis médical.